Pre-clinical and clinical significance of heparanase in Ewing's sarcoma

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 9, 2011, Pages 1857-1864

  Shafat, Itay ^a   Ben Arush, Myriam Weyl ^b   Issakov, Josephine ^c   Meller, Isaac ^c   Naroditsky, Inna ^d   Tortoreto, Monica ^e   Cassinelli, Giuliana ^f   Lanzi, Cinzia ^f   Pisano, Claudio ^f   Ilan, Neta ^a   Vlodavsky, Israel ^a   Zunino, Franco ^e  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MEYER CHILDREN S HOSPITAL   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d Department of Pathology ^*  (Israel)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Sigma Tau SpA   (Italy)

Author keywords

Age; Ewing's sarcoma; Heparanase; SST0001; Tumour size

Indexed keywords

BETA GLUCURONIDASE; DRUG DERIVATIVE; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEPARANASE; HEPARIN; SST 0001;

ADULT; ANIMAL; ARTICLE; CANCER INVASION; CELL FRACTIONATION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EWING SARCOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HEPARIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; SARCOMA, EWING; SUBCELLULAR FRACTIONS; TREATMENT OUTCOME;

EID: 79955866633     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01190.x     Document Type: Article

References (44)

1. Esiashvili N, Goodman M, Marcus RB, Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008; 30: 425-30.
2. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther. 2008; 8: 617-24.
3. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007; 254: 1-10.
4. Paulussen M, Bielack S, Jurgens H, et al. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20: 140-2.
5. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006; 11: 503-19.
6. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000; 25: 349-51.
7. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 2006; 38: 2018-39.
8. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001; 1471: M99-108.
9. Vlodavsky I, Ilan N, Naggi A, et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007; 13: 2057-73.
10. Vreys V, David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007; 11: 427-52.
11. Ferro V, Hammond E, Fairweather JK. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem. 2004; 4: 693-702.
12. McKenzie EA. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol. 2007; 151: 1-14.
13. Miao HQ, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem. 2006; 13: 2101-11.
14. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 2005; 280: 12103-13.
15. Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007; 21: 3562-72.
16. Casu B, Vlodavsky I, Sanderson RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb. 2008; 36: 195-203.
17. Yang Y, MacLeod V, Dai Y, et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood. 2007; 110: 2041-8.
18. Shafat I, Pode D, Peretz T, et al. Clinical significance of urine heparanase in bladder cancer progression. Neoplasia. 2008; 10: 125-30.
19. Shafat I, Zcharia E, Nisman B, et al. An ELISA method for the detection and quantification of human heparanase. Biochem Biophys Res Commun. 2006; 341: 958-63.
20. Shafat I, Ben-Barak A, Postovsky S, et al. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia. 2007; 9: 909-16.
21. Cuccuru G, Lanzi C, Cassinelli G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004; 96: 1006-14.
22. Cohen E, Doweck I, Naroditsky I, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer. 2008; 113: 1004-11.
23. Cohen-Kaplan V, Naroditsky I, Zetser A, et al. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer. 2008; 123: 2566-73.
24. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004; 117: 2249-58.
25. Zhou Z, Reddy K, Guan H, et al. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumorsin vivo. Mol Cancer Res. 2007; 5: 1125-32.
26. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene. 2005; 363: 1-14.
27. Ordonez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res. 2009; 69: 7140-50.
28. Lu WC, Liu YN, Kang BB, et al. Trans-activation of heparanase promoter by ETS transcription factors. Oncogene. 2003; 22: 919-23.
29. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr. 2009; 21: 365-72.
30. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001; 108: 341-7.
31. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18: 3108-14.
32. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, et al. Heparanase induces Akt phosphorylationviaa lipid raft receptor. Biochem Biophys Res Commun. 2007; 361: 829-34.
33. Cohen-Kaplan V, Doweck I, Naroditsky I, et al. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res. 2008; 68: 10077-85.
34. Fux L, Feibish N, Cohen-Kaplan V, et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009; 69: 1758-67.
35. Fux L, Ilan N, Sanderson RD, et al. Heparanase: busy at the cell surface. Trends Biochem Sci. 2009; 34: 511-9.
36. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migrationviaprotein kinase B/Akt activation. J Biol Chem. 2004; 279: 23536-41.
37. Zetser A, Bashenko Y, Edovitsky E, et al. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006; 66: 1455-63.
38. Schubert SY, Ilan N, Shushy M, et al. Human heparanase nuclear localization and enzymatic activity. Lab Invest. 2004; 84: 535-44.
39. Takaoka M, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 2003; 83: 613-22.
40. Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia. 2006; 8: 1055-61.
41. Kobayashi M, Naomoto Y, Nobuhisa T, et al. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation. 2006; 74: 235-43.
42. Ohkawa T, Naomoto Y, Takaoka M, et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest. 2004; 84: 1289-304.
43. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009; 50: 958-68.
44. Ferro V, Dredge K, Liu L, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 2007; 33: 557-68.